

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HOGENKAMP *et al.*

Appl. No.: 09/803,659

Filed: March 12, 2001

For: **Aryl Substituted Pyrimidines**

Confirmation No.: 6633

Art Unit: 1624

Examiner: Balasubramanian, V.

Atty. Docket: 1861.1260001/JMC/THN

RECEIVED
MAR 23 2004
OFFICE OF PETITIONS

Fifth Supplemental Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fifth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Fourth Supplemental Information Disclosure Statement filed February 3, 2003, in connection with the above-captioned application. A copy of each document is also provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language document AO8 cited on Form PTO-1449:

Document AO8, Hungarian Patent Publication No. HU 206 202 B, is in the Hungarian language. English language equivalents of document AO8 are attached as documents AC3, AD3, and AE3.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Fifth Supplemental Information Disclosure Statement is being filed concurrently with a request for continued examination. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



John M. Covert
Attorney for Applicants
Registration No. 38,759

Date: Mar. 26, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600